These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 36076972)

  • 1. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases.
    Diz-Chaves Y; Mastoor Z; Spuch C; González-Matías LC; Mallo F
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
    Kopp KO; Glotfelty EJ; Li Y; Greig NH
    Pharmacol Res; 2022 Dec; 186():106550. PubMed ID: 36372278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
    Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus.
    Diz-Chaves Y; Herrera-Pérez S; González-Matías LC; Mallo F
    Vitam Horm; 2022; 118():457-478. PubMed ID: 35180937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease.
    Verma A; Goyal A
    Eur J Pharmacol; 2024 Nov; 982():176936. PubMed ID: 39182542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives in GLP-1 Research: New Targets, New Receptors.
    Cantini G; Mannucci E; Luconi M
    Trends Endocrinol Metab; 2016 Jun; 27(6):427-438. PubMed ID: 27091492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
    Glotfelty EJ; Olson L; Karlsson TE; Li Y; Greig NH
    Expert Opin Investig Drugs; 2020 Jun; 29(6):595-602. PubMed ID: 32412796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
    Calsolaro V; Edison P
    CNS Drugs; 2015 Dec; 29(12):1023-39. PubMed ID: 26666230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.
    Hölscher C
    CNS Drugs; 2012 Oct; 26(10):871-82. PubMed ID: 22938097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.
    Muscogiuri G; DeFronzo RA; Gastaldelli A; Holst JJ
    Trends Endocrinol Metab; 2017 Feb; 28(2):88-103. PubMed ID: 27871675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.
    Zheng Z; Zong Y; Ma Y; Tian Y; Pang Y; Zhang C; Gao J
    Signal Transduct Target Ther; 2024 Sep; 9(1):234. PubMed ID: 39289339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
    Jia Y; Gong N; Li TF; Zhu B; Wang YX
    Pharmacol Res; 2015 Dec; 102():276-85. PubMed ID: 26546042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
    Hölscher C
    J Endocrinol; 2014 Apr; 221(1):T31-41. PubMed ID: 23999914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C
    Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-Inflammatory Effects of GLP-1R Activation in the Retina.
    Puddu A; Maggi D
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?
    Bassil F; Fernagut PO; Bezard E; Meissner WG
    Prog Neurobiol; 2014 Jul; 118():1-18. PubMed ID: 24582776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
    Mayendraraj A; Rosenkilde MM; Gasbjerg LS
    Peptides; 2022 May; 151():170749. PubMed ID: 35065096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1a: Going beyond Traditional Use.
    Laurindo LF; Barbalho SM; Guiguer EL; da Silva Soares de Souza M; de Souza GA; Fidalgo TM; Araújo AC; de Souza Gonzaga HF; de Bortoli Teixeira D; de Oliveira Silva Ullmann T; Sloan KP; Sloan LA
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of spinal GLP-1 receptor signaling.
    Zhang D; Lv G
    Peptides; 2018 Mar; 101():89-94. PubMed ID: 29329976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.